Literature DB >> 29692361

A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.

Ameet A Chimote1, Andras Balajthy1, Michael J Arnold1, Hannah S Newton1, Peter Hajdu1, Julianne Qualtieri2, Trisha Wise-Draper3, Laura Conforti4.   

Abstract

The limited ability of cytotoxic T cells to infiltrate solid tumors hampers immune surveillance and the efficacy of immunotherapies in cancer. Adenosine accumulates in solid tumors and inhibits tumor-specific T cells. Adenosine inhibits T cell motility through the A2A receptor (A2AR) and suppression of KCa3.1 channels. We conducted three-dimensional chemotaxis experiments to elucidate the effect of adenosine on the migration of peripheral blood CD8+ T cells from head and neck squamous cell carcinoma (HNSCC) patients. The chemotaxis of HNSCC CD8+ T cells was reduced in the presence of adenosine, and the effect was greater on HNSCC CD8+ T cells than on healthy donor (HD) CD8+ T cells. This response correlated with the inability of CD8+ T cells to infiltrate tumors. The effect of adenosine was mimicked by an A2AR agonist and prevented by an A2AR antagonist. We found no differences in A2AR expression, 3',5'-cyclic adenosine monophosphate abundance, or protein kinase A type 1 activity between HNSCC and HD CD8+ T cells. We instead detected a decrease in KCa3.1 channel activity, but not expression, in HNSCC CD8+ T cells. Activation of KCa3.1 channels by 1-EBIO restored the ability of HNSCC CD8+ T cells to chemotax in the presence of adenosine. Our data highlight the mechanism underlying the increased sensitivity of HNSCC CD8+ T cells to adenosine and the potential therapeutic benefit of KCa3.1 channel activators, which could increase infiltration of these T cells into tumors.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29692361      PMCID: PMC6006512          DOI: 10.1126/scisignal.aaq1616

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  55 in total

1.  Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function.

Authors:  Balázs Csóka; Leonóra Himer; Zsolt Selmeczy; E Sylvester Vizi; Pál Pacher; Catherine Ledent; Edwin A Deitch; Zoltán Spolarics; Zoltán H Németh; György Haskó
Journal:  FASEB J       Date:  2008-07-14       Impact factor: 5.191

2.  Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Authors:  Sebastian F M Häusler; Itsaso Montalbán del Barrio; Jenny Strohschein; P Anoop Chandran; Jörg B Engel; Arnd Hönig; Monika Ossadnik; Evi Horn; Birgitt Fischer; Mathias Krockenberger; Stefan Heuer; Ahmed Adel Seida; Markus Junker; Hermann Kneitz; Doris Kloor; Karl-Norbert Klotz; Johannes Dietl; Jörg Wischhusen
Journal:  Cancer Immunol Immunother       Date:  2011-06-03       Impact factor: 6.968

3.  Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.

Authors:  Astrid De Meulenaere; Tijl Vermassen; Sandrine Aspeslagh; Karen Zwaenepoel; Philippe Deron; Fréderic Duprez; Sylvie Rottey; Liesbeth Ferdinande
Journal:  Pathology       Date:  2017-04-17       Impact factor: 5.306

Review 4.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

5.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

6.  Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Authors:  Paul A Beavis; Melissa A Henderson; Lauren Giuffrida; Jane K Mills; Kevin Sek; Ryan S Cross; Alexander J Davenport; Liza B John; Sherly Mardiana; Clare Y Slaney; Ricky W Johnstone; Joseph A Trapani; John Stagg; Sherene Loi; Lev Kats; David Gyorki; Michael H Kershaw; Phillip K Darcy
Journal:  J Clin Invest       Date:  2017-02-06       Impact factor: 14.808

Review 7.  Ion channels and transporters in lymphocyte function and immunity.

Authors:  Stefan Feske; Edward Y Skolnik; Murali Prakriya
Journal:  Nat Rev Immunol       Date:  2012-06-15       Impact factor: 53.106

8.  CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.

Authors:  Bruno G Leclerc; Roxanne Charlebois; Guillaume Chouinard; Bertrand Allard; Sandra Pommey; Fred Saad; John Stagg
Journal:  Clin Cancer Res       Date:  2015-08-07       Impact factor: 12.531

9.  μ-Slide Chemotaxis: a new chamber for long-term chemotaxis studies.

Authors:  Pamela Zengel; Anna Nguyen-Hoang; Christoph Schildhammer; Roman Zantl; Valentin Kahl; Elias Horn
Journal:  BMC Cell Biol       Date:  2011-05-18       Impact factor: 4.241

10.  Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.

Authors:  Si-Rui Ma; Wei-Wei Deng; Jian-Feng Liu; Liang Mao; Guang-Tao Yu; Lin-Lin Bu; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Mol Cancer       Date:  2017-06-07       Impact factor: 27.401

View more
  17 in total

Review 1.  Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application.

Authors:  Nagore Del-Río-Ibisate; Rocío Granda-Díaz; Juan P Rodrigo; Sofía T Menéndez; Juana M García-Pedrero
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  Therapeutically leveraging GABAA receptors in cancer.

Authors:  Debanjan Bhattacharya; Vaibhavkumar S Gawali; Laura Kallay; Donatien K Toukam; Abigail Koehler; Peter Stambrook; Daniel Pomeranz Krummel; Soma Sengupta
Journal:  Exp Biol Med (Maywood)       Date:  2021-10

Review 3.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

Review 4.  Cancer immunoediting and resistance to T cell-based immunotherapy.

Authors:  Michele W L Teng; Mark J Smyth; Jake S O'Donnell
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

Review 5.  Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Authors:  Kevin Sek; Christina Mølck; Gregory D Stewart; Lev Kats; Phillip K Darcy; Paul A Beavis
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

6.  The Trials and Tribulations of Structure Assisted Design of KCa Channel Activators.

Authors:  Heesung Shim; Brandon M Brown; Latika Singh; Vikrant Singh; James C Fettinger; Vladimir Yarov-Yarovoy; Heike Wulff
Journal:  Front Pharmacol       Date:  2019-09-20       Impact factor: 5.810

7.  PD1 blockade enhances K+ channel activity, Ca2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer.

Authors:  Hannah S Newton; Vaibhavkumar S Gawali; Ameet A Chimote; Maria A Lehn; Sarah M Palackdharry; Benjamin H Hinrichs; Roman Jandarov; David Hildeman; Edith M Janssen; Trisha M Wise-Draper; Laura Conforti
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

8.  A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabilities of CD8+ T Cells in Head and Neck Cancer.

Authors:  Ameet A Chimote; Vaibhavkumar S Gawali; Hannah S Newton; Trisha M Wise-Draper; Laura Conforti
Journal:  Front Pharmacol       Date:  2020-02-28       Impact factor: 5.810

9.  KCNN4 is a diagnostic and prognostic biomarker that promotes papillary thyroid cancer progression.

Authors:  Jialiang Wen; Bangyi Lin; Lizhi Lin; Yizuo Chen; Ouchen Wang
Journal:  Aging (Albany NY)       Date:  2020-08-28       Impact factor: 5.682

10.  KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the tumor microenvironment in kidney renal clear cell carcinoma.

Authors:  Shaohua Chen; Chengbang Wang; Xiaotao Su; Xiaodi Dai; Songheng Li; Zengnan Mo
Journal:  Transl Androl Urol       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.